Top Markets
#1 Arowana Arowana +10.12%
#2 Dual Dual +3.59%
#3 WYDE: End Hunger WYDE: End Hunger +2.19%
#4 SIXSEVEN SIXSEVEN +2.17%
#5 TENDIES TENDIES +1.30%
#6 Fabric Protocol Fabric Protocol +1.21%
#7 Orbs Orbs +1.10%
#8 Fractal Bitcoin Fractal Bitcoin +0.91%
#9 Smooth Love Potion Smooth Love Potion +0.89%
#10 Zerebro Zerebro +0.86%
Coin of the day
Arowana Arowana
設定
言語
日本
通貨
USD
テーマ
Psyence Group Inc. Psyence Group Inc.

Psyence Group Inc.

PSYG
株式のランク #38237
Psyence Group Inc. is a life sciences biotechnology company primarily engaged... Psyence Group Inc. is a life sciences biotechnology company primarily engaged in the commercial cultivation and production of psilocybin mushrooms. This naturally sourced psilocybin is intended for therapeutic applications, addressing a broad spectrum of mental health conditions and other medical ailments. The company is actively formulating pharmaceutical-grade psilocybin treatments designed to mitigate psychological trauma and recognized disorders such as anxiety, depression, post-traumatic stress disorder (PTSD), and the emotional distress linked to grief and bereavement. Furthermore, Psyence Group develops, distributes, and sells over-the-counter functional mushroom nutraceuticals, entirely free of psilocybin, under its GOODMIND brand. Established in 2019, the company maintains its headquarters in Toronto, Canada.
株価
$0.08765138
最終同期: 2025-12-23
時価総額
$1.11M
変化（1日）
0.45%
変化（1年）
-28.78%
国
CA
取引 Psyence Group Inc. (PSYG)

カテゴリー

Healthcare
Psyence Group Inc.（PSYG）の配当利回りの履歴
Psyence Group Inc.（銘柄コード: PSYG）の配当利回り（TTM）は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Psyence Group Inc.（PSYG）の2026から2026までの配当利回りの履歴
各年末時点の配当利回り（TTM）
年 配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り（TTM）
企業 配当利回り 国
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
0.56%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
2.04%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
2.72%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
2.69%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
2.58%
US